Medicinova (MNOV) Research & Development (2010 - 2025)

Medicinova (MNOV) has 16 years of Research & Development data on file, last reported at $1.5 million in Q4 2025.

• On a quarterly basis, Research & Development fell 19.08% year-over-year to $1.5 million in Q4 2025; TTM through Dec 2025 was $7.2 million, a 0.55% decrease from a year earlier, with the FY2025 full-year figure at $7.2 million, down 0.55% from the prior year.
• Research & Development for Q4 2025 stood at $1.5 million, down from $1.6 million in the prior quarter.
• Over the last five years, Research & Development for MNOV reached as high as $2.6 million in Q2 2022 and fell as low as $794706.0 in Q3 2023.
• Historically, Research & Development has averaged $1.9 million across 5 years, with a median of $1.8 million in 2024.
• Across the five-year window, Research & Development plunged 67.62% in 2023 and soared 133.97% in 2024, its largest moves.
• Year by year, Research & Development stood at $1.8 million in 2021, then gained by 13.26% to $2.0 million in 2022, then retreated by 17.98% to $1.7 million in 2023, then rose by 15.55% to $1.9 million in 2024, then retreated by 19.08% to $1.5 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $1.5 million in Q4 2025, $1.6 million in Q3 2025, and $2.2 million in Q2 2025.